
SXTP Stock Forecast & Price Target
SXTP Analyst Ratings
Bulls say
60 Degrees Pharmaceuticals Inc. has reported a significant increase in net product revenues, with a 140% rise to $607.6k for FY24 and a notable 223% year-over-year increase in Q3 FY25 net product revenue. The company’s ARAKODA product is demonstrating strong sales growth, evidenced by a 14% increase in deliveries during Q3 FY25, suggesting a solid market demand and potential for further expansion. Additionally, the favorable safety profile of tafenoquine presents opportunities for innovative combination therapies, enhancing the firm's potential commercialization avenues amidst a growing market for infectious disease treatments.
Bears say
60 Degrees Pharmaceuticals Inc is facing a challenging outlook primarily due to a lack of visibility regarding revenue growth, evidenced by a sequential decline in product revenues to $100,000 amid supply constraints. The reported gross loss of approximately $9,000, a stark contrast to the gross profit of $36,000 in Q3 FY24, stems from a one-time inventory write-off, further highlighting the company's financial vulnerabilities. Additionally, low visibility on regulatory approvals for new therapies and potential dilution from financing pose significant risks that could impede the company's financial performance and stock valuation.
This aggregate rating is based on analysts' research of 60 Degrees Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
SXTP Analyst Forecast & Price Prediction
Start investing in SXTP
Order type
Buy in
Order amount
Est. shares
0 shares